ReviewAdvanced drug delivery reviews2018
Phage therapy for respiratory infections.
Review in Advanced drug delivery reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 2 syntheses or guidelines pooled it, 196 citations in OpenAlex.
- Phage Therapy in Bacterial Pneumonia Models: A Systematic Review and Meta-Analysis.Combinatorial chemistry & high throughput screening · 2025Pooled it
- Evolutionary dynamics and research hotspots of phage applications againstFrontiers in microbiology · 2025Pooled it
- Regenerative Microbiology: Harnessing Bacterial Antagonism and Spatiotemporal Signaling for Diabetic Wound Repair.Smart medicine · 2026Review
- A novel jumbo phage infecting Pseudomonas aeruginosa: genomic insights and phylogenetic classification.Archives of microbiology · 2026Article
- The interplay between insect gut microbiota and host immunity in the development and dissemination of antibiotic resistance.Folia microbiologica · 2026Review
- Bacteriophages as Therapeutic Agents for Pulmonary Infections: From Biological Principles to Clinical Applications.Pharmaceutics · 2026Review
- Engineered Bacteriophages: A Next-Generation Platform for Precision Antimicrobials and Therapeutics.Viruses · 2026Review
- Phage Therapy at the Crossroads Between Clinical Promise and Regulatory Challenge.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Next-generation bacteriophage therapeutic systems: CRISPR-based engineering, near-infrared bioimaging, and precision strategies for treating multidrug-resistant and extensively drug-resistant bacterial infections.Frontiers in microbiology · 2026Review
- Phage therapy of perinephric abscess in kidney transplantation recipients caused by drug-resistantmLife · 2025Article
- [Bacteriophages for the treatment of musculoskeletal infections-An overview of clinical use, open questions, and legal framework].Orthopadie (Heidelberg, Germany) · 2025Article
- Gut Virome and Aging: Phage-Driven Microbial Stability and Immune Modulation.Aging and disease · 2025Review
- The Efficacy of Inhaled Phage Cocktail to Prevent Ventilator-Associated Pneumonia in Children: A Double-Blind Clinical Trial.Biomedicines · 2025Article
- Isolation of Lytic Bacteriophages ofVeterinary sciences · 2025Article
- Latest Advances in Inhalable Dry Powder Bacteriophage Therapy for Pulmonary Infections.Pharmaceutics · 2025Review
- Antibiotic-ResistantMicroorganisms · 2025Review
- Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens.Therapeutic delivery · 2025Review
- The Role of Active Packaging in the Defense Against Foodborne Pathogens with Particular Attention to Bacteriophages.Microorganisms · 2025Review
- Exploration of bacteriophage therapy as a viable alternative to combat antibiotic-resistant bacterial infections: A comprehensiveBioinformation · 2025Article
- Evaluating the effect of sodium alginate and sodium carboxymethylcellulose on pulmonary delivery of levofloxacin spray-dried microparticles.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
A respiratory infection caused by antibiotic-resistant bacteria can be life-threatening. In recent years, there has been tremendous effort put towards therapeutic application of bacteriophages (phages) as an alternative or supplementary treatment option over conventional antibiotics. Phages are natural parasitic viruses of bacteria that can kill the bacterial host, including antibiotic-resistant bacteria. Inhaled phage therapy involves the development of stable phage formulations suitable for inhalation delivery followed by preclinical and clinical studies for assessment of efficacy, pharmacokinetics and safety. We presented an overview of recent advances in phage formulation for inhalation delivery and their efficacy in acute and chronic rodent respiratory infection models. We have reviewed and presented on the prospects of inhaled phage therapy as a complementary treatment option with current antibiotics and as a preventative means. Inhaled phage therapy has the potential to transform the prevention and treatment of bacterial respiratory infections, including those caused by antibiotic-resistant bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.